Shares of Haemonetics Corp. (NYSE:HAE) reached a new 52-week high on Monday . The stock traded as high as $37.86 and last traded at $37.80, with a volume of 253,400 shares trading hands. The stock had previously closed at $37.32.

HAE has been the subject of several research analyst reports. Benchmark Co. lowered their price objective on shares of Haemonetics Corp. from $35.00 to $28.00 and set a “hold” rating for the company in a research note on Wednesday, May 11th. Morgan Stanley reiterated a “hold” rating on shares of Haemonetics Corp. in a research note on Thursday, May 12th. BTIG Research reiterated a “hold” rating on shares of Haemonetics Corp. in a research note on Sunday, May 15th. Goldman Sachs Group Inc. upgraded shares of Haemonetics Corp. from a “sell” rating to a “neutral” rating and set a $29.00 price objective for the company in a research note on Monday, May 16th. Finally, Zacks Investment Research upgraded shares of Haemonetics Corp. from a “strong sell” rating to a “hold” rating in a research note on Monday, July 4th. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and one has issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $34.40.

The stock has a 50-day moving average price of $34.03 and a 200-day moving average price of $31.84. The stock’s market cap is $1.94 billion.

Haemonetics Corp. (NYSE:HAE) last released its quarterly earnings data on Monday, August 1st. The company reported $0.25 earnings per share for the quarter, missing analysts’ consensus estimates of $0.28 by $0.03. The firm earned $210 million during the quarter, compared to analysts’ expectations of $205.41 million. The business’s revenue for the quarter was down 1.6% on a year-over-year basis. During the same period in the previous year, the business posted $0.35 earnings per share. On average, analysts anticipate that Haemonetics Corp. will post $1.44 earnings per share for the current fiscal year.

In other news, Director Ronald Merriman sold 4,337 shares of the stock in a transaction that occurred on Wednesday, August 17th. The stock was sold at an average price of $35.14, for a total transaction of $152,402.18. Following the completion of the sale, the director now owns 22,088 shares of the company’s stock, valued at $776,172.32. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Christopher Simon acquired 60,000 shares of the company’s stock in a transaction dated Thursday, August 4th. The shares were bought at an average cost of $35.00 per share, with a total value of $2,100,000.00. The disclosure for this purchase can be found here.

An institutional investor recently raised its position in Haemonetics Corp. stock. Principal Financial Group Inc. raised its position in Haemonetics Corp. (NYSE:HAE) by 5.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 344,105 shares of the company’s stock after buying an additional 16,768 shares during the period. Principal Financial Group Inc. owned 0.68% of Haemonetics Corp. worth $11,094,000 at the end of the most recent reporting period.

Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.